Advertisement

Performance- and cost-benefit analysis of an influenza point-of-care test compared to laboratory-based multiplex RT-PCR in the emergency department

      Introduction

      Influenza poses a heavy burden on emergency departments (ED) and hospital wards. Fast and reliable bedside tests are invaluable in obtaining indications for (cohort) droplet isolation precautions and improving patient flow. We performed a cost-benefit analysis comparing influenza point-of-care testing (POCT) to laboratory-based multiplex ligation-dependent probe amplification.

      Methods

      Data of 275 ED presentations between January-April 2019 were analyzed. Patients received both POCT and MLPA to calculate POCT sensitivity and specificity. Costs were calculated for both a POCT and MLPA scenario, including costs for testing, admission, droplet isolation precautions and cleaning.

      Results

      In our study population, 34 patients (12%) were identified with influenza A. No cases of influenza B were identified. Mean age of the influenza positive patients was 75(18) years and 56% were male. The most common symptoms upon presentation were cough, malaise and fever, with 74%, 56% and 50%, respectively. Compared to MLPA, POCT yielded a sensitivity of 94%, a specificity of 98% and a negative predictive value of 99% for influenza A. Using POCT yielded a cost reduction of €93,26 per patient.

      Conclusions

      Influenza POCT is an accurate and cost-beneficial method to differentiate between admission with or without droplet isolation precautions. It can be useful in clinical decision making and reducing pressure on ED and hospital beds in an influenza peak season, by enabling fast patient flow and cohort isolation.

      Key Words

      To read this article in full you will need to make a payment

      Purchase one-time access:

      Academic & Personal: 24 hour online accessCorporate R&D Professionals: 24 hour online access
      One-time access price info
      • For academic or personal research use, select 'Academic and Personal'
      • For corporate R&D use, select 'Corporate R&D Professionals'

      Subscribe:

      Subscribe to American Journal of Infection Control
      Already a print subscriber? Claim online access
      Already an online subscriber? Sign in
      Institutional Access: Sign in to ScienceDirect

      References

      1. Reukers, Asten V, Brandsema, Dijkstra, Donker, Gageldonk-Lafeber V, et al. Annual report surveillance of influenza and other respiratory infections in the Netherlands: winter 2017/2018 [Internet]. 2018. Available at: http://hdl.handle.net/10029/622145. Accessed June 3, 2021.

        • Rothberg M
        • Haessler S
        • Brown R.
        Complications of viral influenza.
        Am J Med. 2008; 121: 258-264
        • Chartrand C
        • Leeflang M
        • Minion J
        • Brewer T
        • Pai M.
        Accuracy of rapid influenza diagnostic tests: a meta-analysis.
        Ann Intern Med. 2012; 156: 500-511
        • Davis S
        • Allen AJ
        • O'Leary R
        • Power M
        • et al.
        Diagnostic accuracy and cost analysis of the AlereTM i Influenza A&B near-patient test using throat swabs.
        J Hosp Infect [Internet]. 2017; 97301309
        • Woodberry MW
        • Shankar R
        • Cent A
        • Jerome KR
        • Kuypers J.
        Comparison of the simplexa flua/b & rsv direct assay and laboratory-developed real-time pcr assays for detection of respiratory virus.
        J Clin Microbiol. 2013; 51: 3883-3885
        • O'Connell S
        • Conlan C
        • Reidy M
        • Stack C
        • Mulgrew A
        • Baruah J.
        The impact of point-of-care testing for influenza A and B on patient flow and management in a medical assessment unit of a general hospital.
        BMC Res Notes [Internet]. 2020; 13: 1-5
        • Binnicker MJ
        • Espy MJ
        • Irish CL
        • Vetter EA.
        Direct detection of influenza A and B viruses in less than 20 minutes using a commercially available rapid PCR Assay.
        J Clin Microbiol. 2015; 53: 2353-2354
        • Kanwar N
        • Michael J
        • Doran K
        • Montgomery E
        • Selvarangan R.
        Comparison of the ID now influenza A & B 2, cobas influenza A/B, and xpert xpress flu point-of-care nucleic acid amplification tests for influenza A/B virus detection in children.
        J Clin Microbiol. 2020; 58: 1-7
        • Youngs J
        • Marshall B
        • Farragher M
        • et al.
        Implementation of influenza point-of-care testing and patient cohorting during a high-incidence season: a retrospective analysis of impact on infection prevention and control and clinical outcomes.
        J Hosp Infect. 2019; 101: 276-284
        • Berry L
        • Lansbury L
        • Gale L
        • Carroll AM
        • Lim WS.
        Point of care testing of Influenza A/B and RSV in an adult respiratory assessment unit is associated with improvement in isolation practices and reduction in hospital length of stay.
        J Med Microbiol. 2020; 69: 697-704
        • Garvey MI
        • Wilkinson MAC
        • Bradley CW
        • et al.
        Impact of a PCR point of care test for influenza A/B on an acute medical unit in a large UK teaching hospital: Results of an observational, pre and post intervention study.
        Antimicrob Resist Infect Control. 2019; 8: 1-8
        • Brendish NJ
        • Malachira AK
        • Clark TW.
        Molecular point-of-care testing for respiratory viruses versus routine clinical care in adults with acute respiratory illness presenting to secondary care: A pragmatic randomised controlled trial protocol (ResPOC).
        BMC Infect Dis. 2017; 17: 1-8
        • Wabe N
        • Li L
        • Lindeman R
        • Yimsung R
        • et al.
        The impact of rapid molecular diagnostic testing for respiratory viruses on outcomes for emergency department patients.
        Med J Aust. 2019; 210: 316-320
        • Lankelma JM
        • Hermans MHA
        • Hazenberg EHLCM
        • et al.
        Implementation of point-of-care testing and a temporary influenza ward in a Dutch hospital.
        Neth J Med. 2019; 77: 109-115
        • Andrews D
        • Chetty Y
        • Cooper BS
        • et al.
        Multiplex PCR point of care testing versus routine, laboratory-based testing in the treatment of adults with respiratory tract infections: A quasi-randomised study assessing impact on length of stay and antimicrobial use.
        BMC Infect Dis. 2017; 17: 1-11
        • Hansen G
        • Moore J
        • Herding E
        • et al.
        Clinical decision making in the emergency department setting using rapid PCR: Results of the CLADE study group.
        J Clin Virol. 2018; 102: 42-49
        • Brachmann M
        • Kikull K
        • Kill C
        • Betz S.
        Correction to: Economic and operational impact of an improved pathway using rapid molecular diagnostic testing for patients with influenza-like illness in a German emergency department.
        J Clin Monit Comput. 2019; 33 (1129-11. J Clin Monit Comput. 2019;33(6): 1147
        • Rahamat-Langendoen J
        • Groenewoud H
        • Kuijpers J
        • Melchers WJG
        • van der Wilt GJ.
        Impact of molecular point-of-care testing on clinical management and in-hospital costs of patients suspected of influenza or RSV infection: a modeling study.
        J Med Virol. 2019; 91: 1408-1414
        • Chu HY
        • Englund JA
        • Huang D
        • et al.
        Impact of rapid influenza PCR testing on hospitalization and antiviral use: a retrospective cohort study.
        J Med Virol. 2015; 87: 2021-2026
        • Reijans M
        • Dingemans G
        • Klaassen CH
        • et al.
        RespiFinder: A new multiparameter test to differentially identify fifteen respiratory viruses.
        J Clin Microbiol. 2008; 46: 1232-1240
      2. Copan, Innovating Together™, Eswab®, Available at: https://products.copangroup.com/index.php/products/clinical/eswab. Accessed June 3, 2021.